Apimeds Pharmaceuticals US (APUS) Gains from Investment Securities (2025)
Apimeds Pharmaceuticals US (APUS) posted Gains from Investment Securities of -$12859.0 for Q3 2025, down 35.1% on a QoQ basis from -$9518.0 in Q2 2025.
Apimeds Pharmaceuticals US (APUS) Gains from Investment Securities (2025) Analysis & Trends
Apimeds Pharmaceuticals US's Gains from Investment Securities history runs 1 years deep, the most recent figure standing at -$12859.0 for Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 90.13 Bn | 88.27 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.98 Bn | 32.24 Bn | 1.97 Bn |
| 3 | Zoetis | 32.59 Bn | 30.65 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.08 Bn | 20.93 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - |
| 7 | Viatris | 20.38 Bn | 18.57 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.80 Bn | 16.48 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn |
| 10 | Apimeds Pharmaceuticals US | 62.67 Mn | 62.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -12,859.00 |
| Sep 30, 2025 | -12,859.00 |
| Jun 30, 2025 | -9,518.00 |
| Jun 30, 2025 | -9,518.00 |